Taipei, Taiwan, 20 July 2023 -- Lotus Pharmaceutical (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795), a multinational pharmaceutical company, today announced it received the HR Asia 2023 “Best Companies to Work for in Asia”. After rigorous selection, Lotus has stood out among 366 companies and has once again been honored with the prestigious Asian Human Resources Key Indicator Award, demonstrating Lotus' ongoing efforts in business management, and earning recognition and support from our employees. This achievement will further propel Lotus' continuous growth in sustainable business operations.
The "Best Companies to Work for in Asia Award," organized by HR Asia, is one of the most representative HR awards in the Asian region. The judging panel was impressed by Lotus' efforts in nurturing multinational talent and fostering cultural diversity. This award not only undergoes objective evaluation based on publicly available information but also stands out for its unique feature of inviting employees to rate three key aspects: "Corporate Core Culture," "Job Satisfaction," and "Team Thinking and Action." Lotus received high recognition from employees in the "Team Thinking and Action" category, demonstrating the five key pillars of Lotus' STAR MAP: Best Portfolio, Best Quality, Best Service, Low Cost, and Best People. These pillars serve have become a common language for all employees, fostering consensus and propelling the team forward.
Petar Vazharov, Chief Executive Officer of Lotus, said: " In recent years, Lotus has been experiencing a period of rapid growth. I would like to express my gratitude to all our employees for their dedication and their commitment to moving forward alongside the company. While our pace has been fast, we have also seen consensus and cohesion in employee engagement. It is such an honor to receive the Best Employer award from HR Asia once again, which is a tremendous encouragement to Lotus employees, the management, and our shareholders. We will continue to create an equal, friendly, and secure working environment, providing a platform for our global employees to constantly encourage themselves and grow together with the company. "
HR Asia's 'Best Companies to Work for in Asia 2023' award is focusing on the diversity, equality, and inclusivity of companies in the workplace. Lotus's mission is to provide affordable medicine to patients worldwide, and to achieve that. In recent years, it has successfully transformed from a local company specializing in the development of generic drugs into an international pharmaceutical company. As a result, Lotus invites talents from all over the world to join our team. At present, there are more than 1,300 employees in the world, and nearly 10% of the employees in Taiwan are from 14 countries around the world. To facilitate effective internal communication and foster a sense of inclusivity, Lotus has implemented thoughtful initiatives such as customized meals for employees and special celebrations that embrace diverse cultural traditions. These initiatives aim to foster a sense of understanding among all team members and facilitate collaborative cooperation. Additionally, Lotus maintains gender equality within its workforce, with an equal distribution of male and female employees. The ratio of male to female executives stands at 6:4, providing equal opportunities for career advancement.
Lotus is dedicated to enhancing employee engagement through various measures. In terms of compensation, Lotus offers rewards based on employee performance, with annual salaries surpassing market standards. The manufacturing facilities are continuously upgraded to include comfortable rest areas, allowing employees to maximize their productivity after adequate rest. Lotus will continue to create a globally competitive and culturally diverse working environment, providing employees with growth opportunities and a sense of fulfillment in their workplace, ultimately creating optimal value for stakeholders.
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safer and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Susan Liao, IR/PR Director
+886 2 2700 5908